Long-term major histocompatibility complex class I suppression in astronauts and clinical implications

Area of Science:

• Immunology
• Space Medicine
• Molecular Biology

Background:

• Spaceflight impacts astronaut immunity, notably downregulating Major Histocompatibility Complex (MHC) class I gene expression.
• MHC class I suppression is a known immune evasion strategy used by cancer and viruses.
• This downregulation occurs across various mission durations, from short flights to long-duration space station stays.

Purpose of the Study:

• To discuss the long-term health risks associated with sustained MHC class I suppression in astronauts.
• To propose future research avenues for understanding the mechanisms and implications of this immune alteration.
• To outline potential therapeutic strategies for mitigating these risks, with relevance to Earth-based conditions.

Main Methods:

• Review and synthesis of existing literature on spaceflight immunology and MHC class I function.
• Analysis of data from short-term (Inspiration4) and long-duration (ISS) space missions.
• Exploration of known mechanisms of immune evasion and their application to the spaceflight context.

Main Results:

• Consistent downregulation of MHC class I genes observed in astronauts.
• MHC class I suppression identified as a potential risk factor for astronaut health during and post-flight.
• Mechanisms, clinical significance, and therapeutic interventions remain largely unexplored.

Conclusions:

• Sustained MHC class I suppression during spaceflight presents potential long-term health risks.
• Further research is crucial to elucidate underlying mechanisms and clinical outcomes.
• Developing targeted therapies is essential for astronaut health and may benefit terrestrial immune-related diseases.